Table 3. . Incidence of adverse events and aggregate average cost related to their management.

Adverse events grades 3–5 (reported in at least 10% of patients)	Incidence alectinib ALEX (%) [14]	Incidence crizotinib ALEX (%) [14]	Average aggregate cost (updated €, 2018)	Ref.
Anemia	5	1	€1720.99	[18]
Arthralgia	0	1	€1345.88	[19]
Diarrhea	0	2	€298.32	[18]
Peripheral edema	0	1	€489.60	[16]
Fatigue	1	0	€118.95	[20]
Increased ALT	5	15	€1313.96	[20]
Increased AST	5	11	€623.74	[20]
Increased bilirubin in blood	2	0	€1085.64	[20]
Nausea	1	3	€266.68	[18]
Rash	1	0	€1898.28	[20]
Vomiting	0	3	€266.68	[18]